

Multiclonal Outbreak of *Klebsiella pneumoniae* Producing Extended-Spectrum β -Lactamase CTX-M-2 and Novel Variant CTX-M-59 in a Neonatal Intensive Care Unit in Brazil[∇]

Doroti de Oliveira Garcia,^{1,2} Yohei Doi,^{2*} Dora Szabo,³ Jennifer M. Adams-Haduch,² Tânia M. I. Vaz,¹ Daniela Leite,¹ Maria Clara Padoveze,⁴ Maristela P. Freire,⁴ Fernanda P. Silveira,² and David L. Paterson^{2,5,6}

*Instituto Adolfo Lutz, São Paulo, Brazil*¹; *Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania*²; *Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary*³; *Centro de Controle de Doenças, Divisão de Infecção Hospitalar, São Paulo, Brazil*⁴; *University of Queensland, Brisbane, Australia*⁵; and *Queensland Health Pathology Services, Royal Brisbane and Women's Hospital, Brisbane, Australia*⁶

Received 6 November 2007/Returned for modification 30 December 2007/Accepted 1 March 2008

An outbreak of cephalosporin-resistant *Klebsiella pneumoniae* occurred in a neonatal intensive care unit in São Paulo, Brazil. Of the 10 pulsotypes identified during the outbreak and follow-up periods, nine produced CTX-M-2 or its new variant CTX-M-59 and one produced SHV-5. *bla*_{CTX-M-2/59} genes were located on closely related plasmids that were transferable.

Klebsiella pneumoniae has long been known to cause outbreaks of infections in neonatal intensive care units (NICUs). Since the advent of extended-spectrum β -lactamases (ESBLs), many such outbreaks have been associated with ESBL-producing strains (7). Most outbreak investigations of ESBL-producing *K. pneumoniae* in NICUs have attributed the epidemics to dissemination of single clones, whereas only a few studies reported involvement of more than one strain in an outbreak setting (2, 6). We here describe the molecular epidemiology of a multiclonal outbreak in a Brazilian NICU caused by *K. pneumoniae* that produced CTX-M-type ESBLs including CTX-M-59, a novel variant of CTX-M-2.

MATERIALS AND METHODS

Bacterial strains and plasmids. The outbreak occurred in the NICU of a hospital near São Paulo in October 2003. A total of 10 cephalosporin-resistant *K. pneumoniae* strains were isolated at the time. Five were obtained from clinical specimens (one each from blood, cerebrospinal fluid, catheter tip, urine, and oropharynx), four from perirectal swabs, and one from a mother's milk. Subsequently, 37 nonrepetitive, cephalosporin-resistant *K. pneumoniae* strains were isolated from perirectal, axillary, and oropharyngeal swabs during a follow-up investigation between May and August 2004. Additionally, two more strains were identified from a catheter tip and blood culture during the follow-up period. Thus, a total of 49 strains were included in the study.

Escherichia coli DH10B was used as the host for cloning experiments. Chloramphenicol-resistant pBC-SK(-) plasmid (Stratagene, La Jolla, CA) was used as the cloning vector. *E. coli* XL1-Blue Rif^r NA^r was used as the recipient for conjugation and transformation experiments. Bacterial cultures were routinely grown in Luria-Bertani (LB) broth at 37°C.

PFGE. Pulsed-field gel electrophoresis (PFGE) analysis was performed using restriction enzyme XbaI (New England Biolabs, Ipswich, MA) and a CHEF III DR electrophoresis system (Bio-Rad, Hercules, CA). Relatedness of the strains was determined according to the criteria of Tenover et al. (9).

Susceptibility testing. MICs of cefotaxime with and without clavulanic acid, ceftazidime with and without clavulanic acid, cefepime, aztreonam, ertapenem,

ciprofloxacin, and gentamicin were determined for all study strains by use of Etest strips according to the instructions from the manufacturer (AB Biodisk, Solna, Sweden). Production of ESBL was confirmed by the disk diffusion method endorsed by the Clinical and Laboratory Standards Institute (CLSI) (3).

PCR analysis and sequencing. Primer sets to detect *bla*_{TEM} (5), *bla*_{SHV} (10), and *bla*_{CTX-M} (4) were used for PCR analysis to detect the ESBL genes in the study strains. Nucleotide sequencing was performed with an ABI3100 genetic analyzer. The full sequences of *bla*_{CTX-M} genes were obtained using a set of primers flanking the genes (Table 1).

PCR cloning of *bla*_{CTX-M-2/59}. To assess whether the amino acid substitution observed with CTX-M-59 affected the level of resistance to β -lactams, *E. coli* clones producing either CTX-M-2 or CTX-M-59 were constructed. The structural genes corresponding to the enzymes were amplified with primers CTXM2F-XbaI and CTXM2R-BamHI (Table 1). The PCR product was digested with XbaI and BamHI (New England Biolabs) and ligated with pBC-SK(-). *E. coli* DH10B was then transformed by these recombinant plasmids by electroporation. Transformants were selected on LB agar plates containing 50 μ g/ml of ampicillin and 30 μ g/ml of chloramphenicol. After confirmation of the nucleotide sequences, *E. coli* DH10B(pCTX-M-2) producing CTX-M-2 and *E. coli* DH10B(pCTX-M-59) producing CTX-M-59 were used to determine the MICs of β -lactams.

Conjugation and transformation. The standard broth mating method was employed for conjugation experiments (10). Transconjugants were selected on LB agar plates containing 50 μ g/ml of ampicillin, 50 μ g/ml of rifampin, and 50 μ g/ml of nalidixic acid. For the strains that did not yield transconjugants, the plasmids were extracted by the modified alkaline lysis method described previously (8). *E. coli* XL1-Blue Rif^r NA^r was transformed with the plasmids by electroporation. Transformants were selected on LB agar plates containing 50 μ g/ml of ampicillin.

DNA hybridization. Plasmids were extracted from the transconjugants and transformants by the modified alkaline lysis method (8) and digested with EcoRI, HindIII, or PstI (New England Biolabs). The plasmids were then subjected to electrophoresis in an 0.8% agarose gel. The plasmids digested with PstI were hybridized with a digoxigenin-labeled DNA probe specific for *bla*_{CTX-M-2/59} using the PCR DIG detection system (Roche Diagnostics, Indianapolis, IN).

Nucleotide sequence accession numbers. The nucleotide sequences of *bla*_{CTX-M-59} and *bla*_{SHV-85} have been deposited in the GenBank/EMBL/DDBJ database under accession no. DQ408762 and DQ322460, respectively.

RESULTS AND DISCUSSION

PFGE. PFGE revealed the presence of 10 pulsotypes (Table 2; Fig. 1). Pulsotypes A and J were detected solely during the outbreak and were possibly related to each other, while pul-

* Corresponding author. Mailing address: Division of Infectious Diseases, University of Pittsburgh Medical Center, Falk Medical Building, Suite 3A, 3601 Fifth Avenue, Pittsburgh, PA 15213. Phone: (412) 648-6401. Fax: (412) 648-6399. E-mail: doiy@dom.pitt.edu.

[∇] Published ahead of print on 17 March 2008.

TABLE 1. Primers used for the study

Gene	Primer name	Primer sequence	Product size (bp)	Reference
<i>bla_{SHV}</i>	SHV-F-S1	5'-ATTTGTCGCTTCTTT ACTCGC-3'	1,051	10
	SHV-R-S2	5'-TTTATGGCGTTACCT TTGACC-3'		
<i>bla_{TEM}</i>	TEM-F	5'-ATGAGTATTCAACAT TTCCGTG-3'	840	5
	TEM-R	5'-TTACCAATGCTTAAT CAGTGAG-3'		
<i>bla_{CTX-M}</i>	CTX-M/F'	5'-TTTGGCATGTGCAGT ACCAGTAA-3'	544	4
	CTX-M/R'	5'-CGATATCGTTGGTG GTGCCATA-3'		
<i>bla_{CTX-M-2}</i>	CTXM2F	5'-AAATGTGCTGCTCCT TTCCGTGAGC-3'	1,122	This study
	CTXM2R	5'-AGGGTTCGTTGCCAA GACAAGACTG-3'		
	CTXM2F XbaI ^a	5'-CGTCTAGAATGATG ACTCAGAGCA-3'	892	This study
	CTXM2R BamHI ^a	5'-CGGGATCCTCAGAA ACCGTGGGTT-3'		

^a Restriction sites are underlined in the sequences.

sotype B was present both during and after the outbreak. Pulsotypes C and D were commonly recovered during the follow-up period. Taken together, these five pulsotypes accounted for 82% of the study strains.

Susceptibilities of the study strains. All of the study strains were confirmed as ESBL producers by the disk diffusion method. Strains belonging to all pulsotypes except D had median cefotaxime MICs of greater than 256 µg/ml. Strains with pulsotype D had a median ceftazidime MIC of 256 µg/ml but a lower median cefotaxime MIC (48 µg/ml). All strains were susceptible to ertapenem and ciprofloxacin. They were variably resistant to gentamicin.

PCR analysis and sequencing of β-lactamase genes. All PFGE pulsotypes except D gave amplicons consistent with *bla_{CTX-M}*. The sequences corresponded to CTX-M-2 for pulsotypes A, B, F, H, I, and J and CTX-M-59 for pulsotypes C, E, and G (Table 2). CTX-M-59 is a novel variant of CTX-M-2 with an H89L substitution according to the Ambler numbering scheme (1). Pulsotype D carried *bla_{SHV}*, which was confirmed to encode SHV-5 upon sequencing of the full open reading frame. All the other pulsotypes except F were also positive for *bla_{SHV}*, which encoded various non-ESBL SHV enzymes including SHV-1, -11, -77, and -85. SHV-85 is a novel variant of SHV-11 with an L19M substitution, which is located within the signal peptide. All pulsotypes except D were positive for *bla_{TEM}*. The deduced amino acid sequences were consistent with that of TEM-1.

Phenotype conferred by CTX-M-59. The β-lactam MICs of *E. coli* DH10B(pCTX-M-59) did not differ significantly from those of *E. coli* DH10B(pCTX-M-2) (Table 3). Both clones displayed susceptibility patterns typical for organisms producing CTX-M-type enzymes, with higher levels of resistance to cefotaxime than to ceftazidime. These results suggested that the kinetic properties of CTX-M-59 were not likely altered by the H89L substitution compared with its progenitor CTX-M-2.

TABLE 2. MICs and ESBL types of *K. pneumoniae* strains according to PFGE pulsotype^a

Pulsotype	No. of isolates	Yr	Origin(s)	Median MIC (range) (µg/ml) of drug:									
				CAZ	CAZ/CLA	CTX	CTX/CLA	ATM	FEP	ERT	GEN	CIP	ESBL
A	7	2003	Blood, CSF, urine, surveillance	6 (4-16)	0.5 (0.38-2)	>256 (96->256)	0.094 (0.004-0.125)	24 (16-64)	16 (4-64)	1.5 (0.19-4)	>256 (0.5->256)	0.023 (0.023-0.047)	CTX-M-2
B	8	2003/2004	Catheter tip, oropharynx, surveillance	24 (6-48)	0.75 (0.38-4)	>256 (>256)	0.094 (0.004-1)	48 (12-256)	128 (16->256)	1 (0.25-2)	>256 (96->256)	0.032 (0.016-0.047)	CTX-M-2
C	13	2004	Surveillance	4 (3-8)	0.38 (0.25-1)	>256 (256->256)	0.094 (0.004-0.19)	32 (12-256)	256 (12->256)	1.5 (0.19-1.5)	>256 (16->256)	0.032 (0.023-0.032)	CTX-M-59
D	12	2004	Surveillance	256 (96->256)	0.25 (0.19-2)	48 (8-256)	0.047 (0.023-0.125)	256 (48->256)	4 (1->256)	0.094 (0.016-1.5)	24 (0.5->256)	0.023 (0.023-0.047)	SHV-5
E	2	2004	Surveillance	8 (6-8)	0.75 (0.75)	>256 (>256)	0.125 (0.094-0.125)	32 (16-32)	16 (16)	1.5 (0.38-1.5)	>256 (>256)	0.032 (0.032)	CTX-M-59
F	1	2004	Surveillance	8	1.5	>256	0.094	256	>256	1.5	>256	0.25	CTX-M-2
G	2	2004	Surveillance	12 (6-12)	1.0 (0.5-1)	>256 (256->256)	0.5 (0.094-0.5)	64 (16-64)	32 (16-32)	1.5 (0.25-1.5)	>256 (256->256)	0.125 (0.023-0.125)	CTX-M-59
H	2	2004	Blood, catheter tip	256 (96-256)	>4 (>4)	>256 (>256)	1.0 (1.0)	48 (32-48)	>256 (48->256)	2 (0.5-2)	>256 (128->256)	0.023 (0.023)	CTX-M-2
I	1	2004	Surveillance	4	0.5	>256	0.094	24	256	0.094	256	0.032	CTX-M-2
J	1	2003	Surveillance	6	0.75	>256	0.094	128	12	1.5	96	0.023	CTX-M-2

^a Abbreviations: CAZ, ceftazidime; CAZ/CLA, ceftazidime plus clavulanic acid; CTX, cefotaxime; CTX/CLA, cefotaxime plus clavulanic acid; ATM, aztreonam; FEP, cefepime; ERT, ertapenem; GEN, gentamicin; CIP, ciprofloxacin; CSF, cerebrospinal fluid.




FIG. 1. PFGE profiles of the 10 pulsotypes identified in the study. M, marker.

Mating experiments. Transconjugants were obtained from representative strains of all pulsotypes at frequencies of 2×10^{-5} or higher per recipient cell except for pulsotypes A and J, for which no transconjugant was obtained. All transconjugants except for that from pulsotype D were resistant to cefotaxime but not ceftazidime. PCR analysis for these transconjugants yielded amplicons with primers specific for *bla*_{CTX-M-2} and *bla*_{TEM-1}, indicating successful transfer of *bla*_{CTX-M-2/59} and *bla*_{TEM-1}. The transconjugant from pulsotype D was resistant to ceftazidime but not cefotaxime and was positive for *bla*_{SHV-5} by PCR analysis, indicating conjugal transfer of *bla*_{SHV-5}. The plasmids harboring *bla*_{CTX-M-2} in representative strains from profiles A and J were successfully transferred to the recipient strain by transformation, which was confirmed by PCR analysis likewise. The MICs for the transconjugants and transformants are shown in Table 4.

Plasmid analysis and DNA hybridization. Plasmids obtained from the transconjugants and transformants encoding *bla*_{CTX-M-2/59} shared identical or very similar banding patterns with any of the three restriction enzymes, whereas that from the transconjugant encoding *bla*_{SHV-5} was distinct (results not shown). The sizes of these plasmids were estimated to be ca. 50 kb. The probe for *bla*_{CTX-M-2/59} hybridized with two bands with similar sizes, ca. 1.5 kb and 0.5 kb, for the plasmids from all pulsotypes except D (Fig. 2). Two bands were generated because *bla*_{CTX-M-2/59} contains a PstI restriction site. This finding suggested that the

TABLE 3. MICs of *E. coli* DH10B with recombinant plasmids encoding *bla*_{CTX-M-2/59}

<i>E. coli</i> strain	MIC (µg/ml) of drug ^a :						
	CAZ	CAZ/CLA	CTX	CTX/CLA	ATM	FEP	ERT
DH10B(pCTX-M-2)	8	0.38	128	0.094	12	4	0.016
DH10B(pCTX-M-59)	8	0.38	96	0.094	12	4	0.016

^a Abbreviations: CAZ, ceftazidime; CAZ/CLA, ceftazidime plus clavulanic acid; CTX, cefotaxime; CTX/CLA, cefotaxime plus clavulanic acid; ATM, aztreonam; FEP, cefepime; ERT, ertapenem.

TABLE 4. MICs and PCR results for the transconjugants/transformants from each PFGE pulsotype

Pulsotype	Median MIC (µg/ml) of drug ^a :							β-Lactamase(s)	
	CAZ	CAZ/CLA	CTX	CTX/CLA	ATM	FEP	ERT		GEN
A	8	0.19	>256	0.094	>256	>256	0.125	>256	CTX-M-2, TEM-1
B	12	0.19	>256	0.094	256	256	0.125	>256	CTX-M-2, TEM-1
C	8	0.25	>256	0.19	>256	>256	0.064	>256	CTX-M-2, TEM-1
D	>256	0.19	12	0.47	>256	1.5	0.012	24	SHV-5
E	4	0.19	>256	0.25	48	>256	0.094	>256	CTX-M-59, TEM-1
F	16	0.38	>256	0.125	>256	>256	0.125	>256	CTX-M-2, TEM-1
G	8	0.38	>256	0.19	>256	>256	0.125	>256	CTX-M-59, TEM-1
H	8	0.25	>256	0.94	>256	>256	0.094	>256	CTX-M-2, TEM-1
I	6	0.19	>256	0.125	>256	>256	0.032	>256	CTX-M-2, TEM-1
J	12	0.38	>256	0.125	>256	>256	0.094	128	CTX-M-2, TEM-1

^a Abbreviations: CAZ, ceftazidime; CAZ/CLA, ceftazidime plus clavulanic acid; CTX, cefotaxime; CTX/CLA, cefotaxime plus clavulanic acid; ATM, aztreonam; FEP, cefepime; ERT, ertapenem; GEN, gentamicin.




FIG. 2. DNA hybridization with a *bla*_{CTX-M-2}-specific probe. *bla*_{CTX-M-2/59} contains a PstI restriction site. All the plasmids hybridized with the probe, except for that from pulstype D, which is *bla*_{CTX-M-2/59} negative and *bla*_{SHV-5} positive.

genetic support of *bla*_{CTX-M-2/59} in this outbreak was likely uniform regardless of pulstypes. Taken together, the outbreak phase was initiated by three genomic clones carrying similar plasmids, all encoding *bla*_{CTX-M-2}. It appears that one of the plasmids then further disseminated to other clones and produced a variant plasmid encoding *bla*_{CTX-M-59}. Thus, we speculate that these ESBL-encoding plasmids persisted, evolved, and disseminated among different clones of *K. pneumoniae* in the confined environment of a NICU over the 10-month period.

Conclusion. We described a multiclonal outbreak of *K. pneumoniae* producing CTX-M-2 and its variant CTX-M-59 ESBLs which took place in a Brazilian NICU. In addition to the spread of each clonal group, dissemination of identical or related plasmids harboring the CTX-M-type ESBL genes

among different clonal groups was responsible for the persistence of ESBL-producing *K. pneumoniae* over time.

ACKNOWLEDGMENTS

We thank Hanna Sidjabat for expert technical assistance. D.D.O.G. and part of this study were supported by a Fogarty International Center Global Infectious Diseases Research Training Program grant, National Institutes of Health (D43TW006592; principal investigator, Lee H. Harrison). Y.D. is supported by NIH training grant T32AI007333. D.L.P. has received prior research funding from Pfizer, Elan, Merck, and AstraZeneca and is supported in part by NIH grant R01AI070896.

REFERENCES

1. Ambler, R. P., A. F. Coulson, J. M. Frere, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A β -lactamases. *Biochem. J.* **276**:269–270.
2. Boukadida, J., N. Salem, N. Hannachi, K. Monastiri, and N. Snoussi. 2002. Genotypic exploration of a hospital neonatal outbreak due to *Klebsiella pneumoniae* producing extended-spectrum- β -lactamase. *Arch. Pediatr.* **9**:463–468.
3. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Edelstein, M., M. Pimkin, I. Palagin, I. Edelstein, and L. Strachounski. 2003. Prevalence and molecular epidemiology of CTX-M extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in Russian hospitals. *Antimicrob. Agents Chemother.* **47**:3724–3732.
5. Kruger, T., D. Szabo, K. H. Keddy, K. Deeley, J. W. Marsh, A. M. Hujer, R. A. Bonomo, and D. L. Paterson. 2004. Infections with nontyphoidal *Salmonella* species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. *Antimicrob. Agents Chemother.* **48**:4263–4270.
6. Lebessi, E., H. Dellagrammaticas, P. T. Tassios, L. S. Tzouveleki, S. Ioannidou, M. Foustoukou, and N. J. Legakis. 2002. Extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit in the high-prevalence area of Athens, Greece. *J. Clin. Microbiol.* **40**:799–804.
7. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum β -lactamases: a clinical update. *Clin. Microbiol. Rev.* **18**:657–686.
8. Takahashi, S., and Y. Nagano. 1984. Rapid procedure for isolation of plasmid DNA and application to epidemiological analysis. *J. Clin. Microbiol.* **20**:608–613.
9. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J. Clin. Microbiol.* **33**:2233–2239.
10. Yagi, T., H. Kurokawa, N. Shibata, K. Shibayama, and Y. Arakawa. 2000. A preliminary survey of extended-spectrum β -lactamases (ESBLs) in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli* in Japan. *FEMS Microbiol. Lett.* **184**:53–56.